vimarsana.com
Home
Live Updates
New data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary disease : comparemela.com
New data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary disease
WILMINGTON, Del.--(BUSINESS WIRE)--May 19, 2024--
Related Keywords
Japan ,
Cambridge ,
Cambridgeshire ,
United Kingdom ,
Manchester ,
United States ,
American ,
America ,
Lymphopoietin Isoforms ,
Dave Singh ,
Brendan Mcevoy ,
Jillian Gonzales ,
Sharon Barr ,
Global Initiative On Obstructive Lung Disease ,
Centers For Disease ,
International Conference ,
American Thoracic Society ,
National Heart ,
Amgen ,
Astrazeneca ,
American Lung Association ,
University Of Manchester ,
Blood Institute ,
Global Initiative For Chronic Obstructive Lung Disease ,
Confidence Interval ,
Respiratory Pharmacology ,
Executive Vice President ,
Respiratory Questionnaire ,
Asthma Symptoms ,
Prescribing Information ,
Patient Informationandinstructions ,
Obstructive Pulmonary Disease ,
North America ,
Rare Diseases ,
Thoracic Society ,
Blood Eosinophil Count ,
Global Initiative ,
Chronic Obstructive Lung Disease ,
Disease Control ,
Leading Causes ,
Learn More Breathe Better ,
Ultimate Relationship ,
One Year Mortality ,
Their Predictors ,
Patients Hospitalized ,
Nationwide Population Based ,
First Year After Hospitalization ,
Chronic Obstructive Pulmonary ,
Obstructive Lung Disease ,
Atherosclerosis Risk ,
Stromal Lymphopoietin Isoforms ,
Inflammatory Disorders ,
Business Wire ,
comparemela.com © 2020. All Rights Reserved.